PGNY Stock Risk & Deep Value Analysis
Progyny Inc
Healthcare • Healthcare Plans
DVR Score
out of 10
What You Need to Know About PGNY Stock
We analyzed Progyny Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PGNY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is PGNY Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium-High
Execution Risk
Medium
Regulatory Risk
Low-Medium
What Are the Red Flags for PGNY?
- ⚠
Stronger-than-expected competition from new entrants or large healthcare players (e.g., UnitedHealth, Cigna)
- ⚠
Economic downturn leading to reduced employer benefit spending or client churn
- ⚠
Negative regulatory changes impacting fertility coverage or benefit administration
Unlock PGNY Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Progyny Inc (PGNY) Do?
Market Cap
$1.66B
Sector
Healthcare
Industry
Healthcare Plans
Employees
675
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Visit Progyny Inc WebsiteIs PGNY Stock Undervalued?
Unlock the full AI analysis for PGNY
Get the complete DVR score, risk analysis, and more
Is PGNY Financially Healthy?
P/E Ratio
32.78
Does PGNY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Progyny's moat is strengthening due to its growing network of high-quality providers and increasing employer adoption, which creates significant switching costs for clients and makes it difficult for new entrants to replicate the scale and clinical outcome data. The 'Smart Cycle' model itself, backed by proprietary data, is an intangible asset that improves with more utilization.
Moat Erosion Risks
- •Aggressive pricing or bundled offerings from larger, integrated healthcare providers
- •Direct-to-consumer fertility tech startups gaining traction and bypassing employer channels
- •Changes in employee benefit preferences reducing demand for specialized fertility benefits
PGNY Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive PGNY Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April/early May 2026)
- •Announcement of significant new employer client wins (Q2 2026)
- •Expansion of 'Smart Cycle' services to cover additional family-building options
Medium-Term (6-18 months)
- •Further penetration into the large employer market (Fortune 500 companies)
- •Potential strategic partnerships to integrate with broader HR/benefits platforms
- •Expansion of provider network into underserved geographic regions
Long-Term (18+ months)
- •Establishment as the dominant, go-to platform for all fertility and family-building benefits
- •Data monetization opportunities from extensive 'Smart Cycle' outcomes data
- •Potential international market expansion beyond current scope
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PGNY?
- ✓
Acceleration in new client logos and covered lives, particularly large enterprises
- ✓
Maintenance or expansion of gross margins and progress towards sustainable profitability
- ✓
Evidence of continued high clinical success rates and patient satisfaction via 'Smart Cycle' data
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PGNY (Progyny Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
